Specific Anticonvulsants Increase Suicide Risk

A large-scale Harvard meta-analysis published in the Journal of the American Medical Association, is the first ever to evaluate the relationship between different anticonvulsant drugs and the risk of suicide in for patients with diverse diagnoses: " the risk was derived from the specific drug that the patient was taking and not their underlying conditions." Continue reading →

Criminal Drug Marketing Remains an Issue

In December, 2009, Bloomberg News published an investigative report by David Evans reported, "Big Pharma’s Crime Spree"   documenting major court settlements: "Pfizer, Eli Lilly & Co., Bristol-Myers Squibb Co. and four other drug companies have paid a total of $7 billion . . . Continue reading →

Is the Schizophrenia Mortality Study in The Lancet CREDIBLE?

Unless the overall treatment and services provided to schizophrenia patients in Finland is unique and especially protective—which the authors do not suggest—their claimed findings of lowered mortality rates for antipsychotic drug users are belied by a consistent body of evidence. 

Continue reading →